These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 7866205)

  • 61. Fatigue Improvement after Switching Multiple Sclerosis Treatment from Interferon-β to Glatiramer Acetate in Clinical Practice.
    Meca-Lallana J; Hernández L; Caminero AB; Girón JM; Cano-Orgaz A; Carcelén-Gadea M; Muñoz D; Durán-Ferreras E; Martín-Hernández J; Sánchez-de la Rosa R;
    Eur Neurol; 2016; 76(1-2):40-7. PubMed ID: 27376845
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Interferon beta in multiple sclerosis.
    Gross M
    Lancet; 1999 Aug; 354(9177):512; author reply 512-3. PubMed ID: 10465198
    [No Abstract]   [Full Text] [Related]  

  • 63. Editorial: the pitfalls of combination therapy.
    Vermersch P
    Int MS J; 2006 Nov; 13(3):75-6. PubMed ID: 17101074
    [No Abstract]   [Full Text] [Related]  

  • 64. International consensus statement on the use of disease-modifying agents in multiple sclerosis.
    Freedman MS; Blumhardt LD; Brochet B; Comi G; Noseworthy JH; Sandberg-Wollheim M; Soelberg SP;
    Mult Scler; 2002 Feb; 8(1):19-23. PubMed ID: 11936483
    [TBL] [Abstract][Full Text] [Related]  

  • 65. A prospective, open-label treatment trial to compare the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing--remitting multiple sclerosis: results after 18 months of therapy.
    Khan OA; Tselis AC; Kamholz JA; Garbern JY; Lewis RA; Lisak RP
    Mult Scler; 2001 Dec; 7(6):349-53. PubMed ID: 11795454
    [TBL] [Abstract][Full Text] [Related]  

  • 66. PEGylated interferon beta-1a: meeting an unmet medical need in the treatment of relapsing multiple sclerosis.
    Baker DP; Pepinsky RB; Brickelmaier M; Gronke RS; Hu X; Olivier K; Lerner M; Miller L; Crossman M; Nestorov I; Subramanyam M; Hitchman S; Glick G; Richman S; Liu S; Zhu Y; Panzara MA; Davar G
    J Interferon Cytokine Res; 2010 Oct; 30(10):777-85. PubMed ID: 20836711
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Narrative review of the literature on adherence to disease-modifying therapies among patients with multiple sclerosis.
    Menzin J; Caon C; Nichols C; White LA; Friedman M; Pill MW
    J Manag Care Pharm; 2013; 19(1 Suppl A):S24-40. PubMed ID: 23383731
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Trial of interferon-beta in multiple sclerosis stopped early.
    Bonn D
    Lancet; 1998 Feb; 351(9102):573. PubMed ID: 9492786
    [No Abstract]   [Full Text] [Related]  

  • 69. Use of interferon beta 1b for multiple sclerosis. Manufacturer defends the drug.
    Longthorne PN
    BMJ; 1996 Nov; 313(7067):1263. PubMed ID: 8939141
    [No Abstract]   [Full Text] [Related]  

  • 70. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.
    Lancet; 1998 Nov; 352(9139):1498-504. PubMed ID: 9820297
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Spotlight on subcutaneous recombinant interferon-beta-1a (Rebif) in relapsing-remitting multiple sclerosis.
    Murdoch D; Lyseng-Williamson KA
    BioDrugs; 2005; 19(5):323-5. PubMed ID: 16207073
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data.
    Bell C; Graham J; Earnshaw S; Oleen-Burkey M; Castelli-Haley J; Johnson K
    J Manag Care Pharm; 2007 Apr; 13(3):245-61. PubMed ID: 17407391
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE trial.
    Byrne E
    Neurology; 2003 Jun; 60(11):1872; author reply 1872-3. PubMed ID: 12796564
    [No Abstract]   [Full Text] [Related]  

  • 74. Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations.
    ; Wiendl H; Toyka KV; Rieckmann P; Gold R; Hartung HP; Hohlfeld R
    J Neurol; 2008 Oct; 255(10):1449-63. PubMed ID: 19005625
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Cost-effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis.
    Prosser LA; Kuntz KM; Bar-Or A; Weinstein MC
    Value Health; 2004; 7(5):554-68. PubMed ID: 15367251
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Interferon beta treatment for multiple sclerosis.
    Herndon RM
    Lancet; 1999 Feb; 353(9151):494-5; author reply 497-8. PubMed ID: 9989739
    [No Abstract]   [Full Text] [Related]  

  • 77. New treatments for multiple sclerosis.
    Hutchinson M
    Ir Med J; 1996; 89(2):44. PubMed ID: 8682623
    [No Abstract]   [Full Text] [Related]  

  • 78. [Disease-modifying treatments in multiple sclerosis].
    Confavreux C; Bouhour F; Vukusic S
    Rev Prat; 1999 Nov; 49(17):1882-9. PubMed ID: 10598505
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Disease-modifying drugs for the early treatment of multiple sclerosis.
    Flachenecker P
    Expert Rev Neurother; 2004 May; 4(3):455-63. PubMed ID: 15853542
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Does interferon beta cause initial exacerbation of multiple sclerosis?
    Rudge P; Miller D; Crimlisk H; Thorpe J
    Lancet; 1995 Mar; 345(8949):580. PubMed ID: 7776786
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.